Damien Tremolet

Clinimetrics SA provides market research services. The private company is based in Rixensart, Belgium. The Belgian company was founded in 1985. Marc Buyse has been the CEO of the company since 2007.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

Alain Oncologie Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

Ad Bio Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life.

Part of PharmaEngine, Inc., Pharmaengine Europe SARL develops pharmaceutical products for cancer diseases. The company is based in Paris, France. The CEO of the French company is Alain Herrera.

Gustave Roussy Transfert is a subsidiary of Gustave Roussy, the first cancer control center in France, which places innovation at the heart of care and research against cancer. The private company is based in Villejuif, France. The French company's main mission is to identify, protect, promote, and support the scientific, technological, and medical resources of Gustave Roussy. Gustave Roussy Transfert has designed a program called "Better Living Cancer" to support cancer patients during and after treatments through complementary approaches and practices to improve their quality of life. The program includes physical activity sessions, mindfulness meditation courses, and aesthetic care.

EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed.

Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston.

Luciad NV designs and develops visualization and geospatial software products. The firm’s solutions include browser, server, AIXM 5 viewer, desktop, mobile, air traffic control and lucy test drive. The company was founded by Lode Missiaen and Thierry Salvant in 1999 and is headquartered in Leuven, Belgium.

Phasya SA develops technologies and products for detecting drowsiness and measuring eye movements. It offers solutions for analyzing eye images and for detecting physiological and cognitive states from eye images. The company was founded by Jerome Wertz, Thomas Langohr, Thomas Hoyoux, Clementine Francois and Jacques G. Verly on December 5, 2014 and is headquartered in Seraing, Belgium.

AARDEX Group (Switzerland) SA manufactures medication event monitoring systems. . The company was founded by Bernard Vrijens in 1984 and is headquarterd in Sion, Switzerland.

OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

KitoZyme SA manufactures biopolymers and provides medical device products. It develops and produces chitosan (and derivatives), chitin-glucan and beta-glucan, exclusively extracted from renewable, non-GMO vegetable sources. The firm specializes in weight management, digestive health and cardiovascular health products. The company was founded in December 2000 and is headquartered in Herstal, Belgium.

KiOmed Pharma SA develops pharmaceutical products. It offers animal-free, ultrapure chitosan-based breakthrough biomaterials for the development of safer and highly efficient therapeutic medical devices and implants for joint health, ophthalmology, tissue engineering and biosurgery. The company was founded by Francois Blondel and Yves Henrotin in 2015 and is headquartered in Herstal, Belgium.

CluePoints SA is a risk based monitoring and central statistical monitoring solution. It offers risk assessment, key risk indicators, data quality oversight and site inspection readiness solutions. The company was founded by Marc Buyse in 2012 and is headquartered in Mont-Saint-Guibert, Belgium.

Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France.

Part of Servier SAS, Institut de Recherches Internationales Servier is a French company that provides scientific research and development services. The company is based in Suresnes, France.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom.

Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France.

Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products.

NETRIS Pharma SAS develops targeted therapies for the treatment of cancer. The company is based in Lyon, France. The French company was founded in 2008 by Patrick Mehlen, Agnès Bernet. Patrick Mehlen has been the CEO since 2008.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.